Dear Editor, Cutaneous T-cell lymphomas (CTCLs) are rare non-Hodgkin lymphomas, affecting 8.8 per 1 000 000 people annually.
1 Bexarotene is the only retinoid approved by the US Food and Drug Administration for mycosis fungoides (MF),
2 the most common CTCL subtype, but its use is limited by high cost and adverse effects, particularly thyroid and lipid abnormalities.
3 Acitretin, a less expensive second-generation retinoid used in psoriasis, is prescribed off-label in MF, yet supporting data remain limited to small retrospective case series.
4 However, our clinical experience suggests dose-dependent efficacy with acitretin, supporting formal evaluation of its dose–response pattern in MF.